Fine Fettle, a major cannabis dispensary operator in Connecticut, completes its shift to hybrid stores across the state this week. All nine locations now sell to both medical patients and recreational buyers, addressing a sharp decline in the medical program. The move responds to falling patient numbers and revenue since recreational sales launched in early 2023.
Medical Program Faces Steep Decline Amid Recreational Expansion
Connecticut's registered medical cannabis patients dropped from nearly 49,000 to under 32,000 since recreational sales began. Medical sales, which carry no tax, fell by $21 million last year, pulling total cannabis revenue to $290 million from $293 million in 2024, per state Department of Consumer Protection data. Recreational sales rose by $17.5 million, but the offset failed to compensate.
Patients Seek Options Beyond State Borders
Experts observe that many medical patients allow registrations to lapse without shifting to recreational purchases in Connecticut. They turn instead to neighboring states offering higher-potency products or to online vape shops and gas stations selling hemp items. Connecticut cannabis ombudsman Erin Gorman Kirk highlighted pressures from surrounding states, noting that Fine Fettle's expansion could shorten travel for some patients.
Legislative Changes Enable Swift Hybrid Conversions
A June 2025 law allows recreational retailers to convert to hybrid licenses without a lottery. It eased pharmacist requirements: stores now need one on site for at least one eight-hour shift weekly, with telehealth available otherwise. Fine Fettle chief operating officer Ben Zachs said these provisions prevented staff reductions and let pharmacists serve more patients across nine sites.
Expansions Demand Major Investments and Upgrades
Zachs described extensive preparations: creating private consultation spaces, rethinking schedules, retraining staff, building remote verification systems, redesigning menus, and passing inspections. Medical products come at lower margins and cheaper prices, requiring broader inventory. Despite costs, Fine Fettle expects gains from improved patient access and word-of-mouth referrals.
